Value of Comparative Oncology Clinical Trials in Companion Species
UCD School of Veterinary Medicine host a seminar entitled 'Defining the value of comparative oncology clinical trials in companion species: A One Medicine approach presented by David M. Vail, DVM (School of Veterinary Medicine and the Carbone Comprehensive
Cancer Center, University of Wisconsin-Madison).
The event takes place in Veterinary Sciences Centre L116 at 1pm on Wednesday 1st March 2017.
Comparative oncology can be used to describe a discipline that integrates the study of naturally occurring cancers in animals into studies of human cancer biology and therapy. The term is most often used when referring to the study of cancers seen in companion (pet) animals. Over the past decade, tremendous growth in the field of comparative oncology has occurred, including significant increases in organized consortium infrastructure, availability of investigational reagents and regulatory standardization. These advances, all in the spirit of the concept of “One Medicine” are currently being applied to the development of novel cytotoxic, immunologic, and biology-based anticancer therapies, innovative drug delivery systems, identification and validation of biological endpoints, noninvasive imaging techniques and surrogate markers critical to the design of human clinical trials. The comparative oncology approach was publically endorsed in North America by the convening of a National Cancer Policy Forum hosted by the Institute of Medicine, National Academy of Sciences in Washington, DC in 2015. Additionally, the biotechnology and pharmaceutical industries recognize the utility of comparative oncology and several examples exist where studies have been initiated in companion species to assist in human cancer drug development. Consideration of the questions that can be asked using comparative oncology methodology define the translational value of this approach. Several examples will be presented that illustrate the concept of comparative oncology clinical trials.
David M. Vail, DVM
Diplomate ACVIM (Oncology)
Professor and Barbara A. Suran Chair in Comparative Oncology
School of Veterinary Medicine and the Carbone Comprehensive Cancer Center
University of Wisconsin-Madison
Dr. Vail received his DVM from the University of Saskatchewan in 1984 and subsequently completed an internship in small animal medicine and surgery at Colorado State University prior to practicing in his native western Canada for two years. He followed up with a residency in Medical Oncology at the Animal Cancer Center at Colorado State University, completed in 1990. He is currently Professor and
Barbara A. Suran Chair in Comparative Oncology at the University of Wisconsin-Madison and a member of the UW Carbone Comprehensive Cancer Center.
Dr. Vail has published over 140 peer-reviewed scientific manuscripts and 50 book chapters in the field of veterinary and comparative oncology. David is co-editor of the textbook Small Animal Clinical Oncology and currently serves as President of the Veterinary Cancer Society. He is the past Chairman of the Scientific Advisory Boards for both the Morris Animal Foundation and the American College of
Veterinary Internal Medicine Foundation, past President of the Canine Comparative Oncology and Genomics Consortium (CCOGC), a founding member of the Comparative Oncology Trials Consortium (COTC) and past North American journal editor for Veterinary and Comparative Oncology. He has been honored as the recipient of both the Mark L. Morris Sr. Distinguished Research Award and the Pfizer
Award for Veterinary Research Excellence.
Please note that this event is not organised by the UCD School of Medicine. Details are posted here to help publicise the event. The School does not accept responsibility for any inaccuracies or changes to the event which may occur. Please liaise directly with the event organisers.